Table 1a.
Patient demographics (n = 241)
| Characteristic | Patients |
|---|---|
|
| |
| Median age (range) | 57 (20–73) |
|
| |
| Male gender, n (%) | 134 (56) |
|
| |
| Donor/Recipient gender, n (%) | |
| Female to male | 46 (19) |
| Other | 195 (81) |
|
| |
| Donor*, n (%) | |
| MRD | 90 (37) |
| MMRD | 3 (1) |
| MUD | 100 (42) |
| MMUD | 48 (20) |
|
| |
| Patient CMV serostatus, n (%) | |
| Seronegative | 105 (44) |
| Seropositive or equivocal | 136 (56) |
|
| |
| Diagnosis, n (%) | |
| Acute myeloid leukemia | 162 (67) |
| Acute lymphoblastic leukemia | 29 (12) |
| Myelodysplastic syndrome | 50 (21) |
|
| |
| Disease risk, n (%) | |
| Low | 5 (2) |
| Intermediate | 207 (81) |
| High | 43 (17) |
|
| |
| Disease status for acute leukemia, n (%)+ | |
| CR1 | 155 (81) |
| CR2–3 | 36 (19) |
|
| |
| HCT-CI, n (%) | |
| 0 | 41 (17) |
| 1–2 | 88 (37) |
| ≥3 | 112 (46) |
|
| |
| Conditioning regimen, n (%) | |
| Bu/Mel/Flu | 147 (61) |
| Cy/Thiotepa/TBI (1375cGy) | 77 (32) |
| Clo/Mel/Thio | 11 (5) |
| Flu/Thiotepa/TBI (1375cGy) | 6 (2) |
|
| |
| Year of HSCT, n (%) | |
| 2008–2010 | 97 (40) |
| 2011–2014 | 144 (60) |
Abbreviations: n, number; MRD, matched-related donor; MMRD, mismatched-related donor; MUD, matched-unrelated donor; MMUD, mismatched-related donor; CMV, cytomegalovirus; CR, complete remission; HCT-CI, Hematopoietic Cell Transplantation Comorbidity Index; Cy, cyclophosphamide; Flu, fludarabine; TBI, total body irradiation; Clo, clofarabine; Mel, melphalan.
*
At 8 allele level (-A,-B,-C and -DRB1).
+
Percentage calculated based on acute leukemia patients only.